EXPLANATION-Matter enclosed in bold-faced brackets [thus] in this bill is not enacted
and is intended to be omitted in the law.
FIRST REGULAR SESSION
SENATE BILL NO. 763
103RD GENERAL ASSEMBLY
INTRODUCED BY SENATOR NICOLA.
2976S.01I KRISTINA MARTIN, Secretary
AN ACT
To repeal section 195.017, RSMo, and to enact in lieu thereof two new sections relating to
abortifacient drugs, with penalty provisions.
Be it enacted by the General Assembly of the State of Missouri, as follows:
Section A. Section 195.017, RSMo, is repealed and two new 1
sections enacted in lieu thereof, to be known as sections 2
195.017 and 579.018, to read as follows:3
195.017. 1. The department of health and senior 1
services shall place a substance in Schedule I if it finds 2
that the substance: 3
(1) Has high potential for abuse; and 4
(2) Has no accepted medical use in treatment in the 5
United States or lacks accepted safety for use in treatment 6
under medical supervision. 7
2. Schedule I: 8
(1) The controlled substances listed in this 9
subsection are included in Schedule I; 10
(2) Any of the following opiates, including their 11
isomers, esters, ethers, salts, and salts of isomers, 12
esters, and ethers, unless specifically excepted, whenever 13
the existence of these isomers, esters, ethers and salts is 14
possible within the specific chemical designation: 15
(a) Acetyl-alpha-methylfentanyl (N-(1-(1-methyl-2- 16
phenethyl)-4-piperidinyl)-N-phenylacetamide); 17
(b) Acetylmethadol; 18 SB 763 2
(c) Acetyl fentanyl (N-(1-phenethylpiperidin-4-yl)-N- 19
phenylacetamide); 20
(d) Acryl fentanyl (-(1-phenethylpiperidin-4-yl)-N- 21
phenylacrylamide); 22
(e) AH-7921(3,4-dichloro-N-[(1-dimethylamino) 23
cyclohexylmethyl] benzamide); 24
(f) Allylprodine; 25
(g) Alphacetylmethadol (except levoalphacetylmethadol, 26
also known as levo-alpha-acetylmethadol levothadyl acetate 27
or LAAM); 28
(h) Alphameprodine; 29
(i) Alphamethadol; 30
(j) Alpha-methylfentanyl (N-1-(alphamethyl-beta- 31
phenyl) ethyl-4-piperidyl) propionanilide; 1 -(1-methyl-2- 32
phenylethyl)-4 ((N-propanilido) piperidine); 33
(k) Alpha-methylthiofentanyl (N -(1-methyl-2-(2- 34
thienyl) ethyl-4-piperidinyl)-N-phenylpropanamide); 35
(l) Benzethidine; 36
(m) Betacetylmethadol; 37
(n) Beta-hydroxyfentanyl (N-(1-(2-hydroxy-2-phenethyl)- 38
4-piperidinyl)-N-phenylpropanamide); 39
(o) Beta-hydroxy-3-methylfentanyl (N-(1-(2-hydroxy-2- 40
phenethyl)-3-methyl-4-piperidinyl)-N-phenylpropanamide); 41
(p) Betameprodine; 42
(q) Betamethadol; 43
(r) Betaprodine; 44
(s) Clonitazene; 45
(t) Dextromoramide; 46
(u) Diampromide; 47
(v) Cyclopropyl fentanyl; 48
(w) Diethylthiambutene; 49
(x) Difenoxin; 50 SB 763 3
(y) Dimenoxadol; 51
(z) Dimepheptanol; 52
(aa) Dimethylthiambutene; 53
(bb) Dioxaphetyl butyrate; 54
(cc) Dipipanone; 55
(dd) Ethylmethylthiambutene; 56
(ee) Etonitazene; 57
(ff) Etoxeridine; 58
(gg) 4-fluoroisobutyryl fentanyl -(4-fluorophenyl)-N- 59
(1-phenethylpiperidin-4-yl)isobutyramide; 60
(hh) Furanyl fentanyl -(1-phenethylpiperidin-4-yl)-N- 61
phenylfuran-2-carboxamide; 62
(ii) Furethidine; 63
(jj) Hydroxypethidine; 64
(kk) Ketobemidone; 65
(ll) Levomoramide; 66
(mm) Levophenacylmorphan; 67
(nn) 3-Methylfentanyl (N-(3-methyl-1-(2-phenylethyl)-4- 68
piperidyl)-N-phenylproanamide), its optical and geometric 69
isomers, salts, and salts of isomers; 70
(oo) 3-Methylthiofentanyl (N -((3-methyl-1-(2- 71
thienyl)ethyl-4-piperidinyl)-N-phenylpropanamide); 72
(pp) Methoxyacetyl fentanyl (2 -methoxy-N-(1- 73
phenethylpiperidin-4-yl)-N-phenylacetamide); 74
(qq) Morpheridine; 75
(rr) MPPP (1-methyl-4-phenyl-4-propionoxypiperidine); 76
(ss) MT-45(1-cyclohexyl-4-(1,2-diphenylethyl) 77
piperazine); 78
(tt) Noracymethadol; 79
(uu) Norlevorphanol; 80
(vv) Normethadone; 81
(ww) Norpipanone; 82 SB 763 4
(xx) Ocfentanil N-(2-fluorophenyl)-2-methoxy-N-(1- 83
phenethylpiperidin-4-yl)acetamide; 84
(yy) Ortho-fluorofentanyl (N-2-(1-phenethylpiperidin- 85
yl)propionamide); other name 2 -fluorofentanyl; 86
(zz) para-fluorobutyryl fentanyl (N -4-fluorophenyl)-N- 87
(1-phenethylpiperidin-4-yl)butyramide; 88
(aaa) Para-fluorofentanyl (N-(4-fluorophenyl)-N-(1-(2- 89
phenethyl)-4-piperidinyl) propanamide; 90
(bbb) PEPAP (1-(2-phenethyl)-4-phenyl-4- 91
acetoxypiperidine); 92
(ccc) Phenadoxone; 93
(ddd) Phenampromide; 94
(eee) Phenomorphan; 95
(fff) Phenoperidine; 96
(ggg) Piritramide; 97
(hhh) Proheptazine; 98
(iii) Properidine; 99
(jjj) Propiram; 100
(kkk) Racemoramide; 101
(lll) Tetrahydrofuranyl fentanyl (N -(1- 102
phenethylpiperidin-4-yl)-N-phenyltetrahydrofuran -2- 103
carboxamide); 104
(mmm) Thiofentanyl (-phenyl-N-(1-(2-thienyl)ethyl-4- 105
piperidinyl)-propanamide; 106
(nnn) Tilidine; 107
(ooo) Trimeperidine; 108
(3) Any of the following opium derivatives, their 109
salts, isomers and salts of isomers unless specifically 110
excepted, whenever the existence of these salts, isomers and 111
salts of isomers is pos sible within the specific chemical 112
designation: 113
(a) Acetorphine; 114 SB 763 5
(b) Acetyldihydrocodeine; 115
(c) Benzylmorphine; 116
(d) Codeine methylbromide; 117
(e) Codeine-N-Oxide; 118
(f) Cyprenorphine; 119
(g) Desomorphine; 120
(h) Dihydromorphine; 121
(i) Drotebanol; 122
(j) Etorphine (except hydrochloride salt); 123
(k) Heroin; 124
(l) Hydromorphinol; 125
(m) Methyldesorphine; 126
(n) Methyldihydromorphine; 127
(o) Morphine methylbromide; 128
(p) Morphine methylsulfonate; 129
(q) Morphine-N-Oxide; 130
(r) Myrophine; 131
(s) Nicocodeine; 132
(t) Nicomorphine; 133
(u) Normorphine; 134
(v) Pholcodine; 135
(w) Thebacon; 136
(4) Any of the following opiate similar synthetic 137
substances scheduled by the U.S. Drug Enforcement 138
Administration as substances that share a pharmacological 139
profile similar to fentanyl, morphine, and other synthetic 140
opioids, unless specifically excepted or unless listed in 141
another schedule: 142
(a) Butyryl fentanyl (N-(1-phenethylpiperidin-4-yl)-N- 143
phenylbutyramide); 144
(b) U-47700 (3,4-Dichloro-N-[2-(dimethylamino) 145
cyclohexyl]--methyl benzamide). 146 SB 763 6
(5) Any material, compound, mixture or preparation 147
which contains any quantity of the following hallucinogenic 148
substances, their salts, isomers and salts of isomers, 149
unless specifically excepted, whenever the existence of 150
these salts, isomers, and salts of isomers is possible 151
within the specific chemical designation: 152
(a) Alpha-ethyltryptamine; 153
(b) 4-bromo-2,5-dimethoxyamphetamine; 154
(c) 4-bromo-2,5-dimethoxyphenethylamine; 155
(d) 2,5-dimethoxyamphetamine; 156
(e) 2,5-dimethoxy-4-ethylamphetamine; 157
(f) 2,5-dimethoxy-4-(n)-propylthiophenethylamine; 158
(g) 2-(2,5-Dimethoxy-4-(n)-propylphenyl) ethanamine; 159
(h) 2-(2,5-Dimethoxy-4-ethylphenyl) ethanamine; 160
(i) 2-(2,5-Dimethoxy-4-methylphenyl) ethanamine; 161
(j) 2-(2,5-Dimethoxy-4-nitro-phenyl) ethanamine; 162
(k) 2-(2,5-Dimethoxyphenyl) ethanamine; 163
(l) 2-(4-Chloro-2,5-dimethoxyphenyl) eth anamine; 164
(m) 2-(4-Ethylthio-2,5-dimethoxyphenyl) ethanamine; 165
(n) 2-(4-Iodo-2,5-dimethoxyphenyl) ethanamine; 166
(o) 2-(4-Isopropylthio)-2,5-dimethoxyphenyl) 167
ethanamine; 168
(p) 4-methoxyamphetamine; 169
(q) 5-methoxy-3,4-methylenedioxyamphetamine; 170
(r) 4-methyl-2, 5-dimethoxyamphetamine; 171
(s) 3,4-methylenedioxyamphetamine; 172
(t) 3,4-methylenedioxymethamphetamine; 173
(u) 3,4-methylenedioxy-N-ethylamphetamine; 174
(v) N-hydroxy-3, 4-methylenedioxyamphetamine; 175
(w) 3,4,5-trimethoxyamphetamine; 176
(x) 5-MeO-DMT or 5-methoxy-N,N-dimethyltryptamine; 177
(y) Alpha-methyltryptamine; 178 SB 763 7
(z) Bufotenine; 179
(aa) Diethyltryptamine; 180
(bb) Dimethyltryptamine; 181
(cc) 5-methoxy-N,N-diisopropyltryptamine; 182
(dd) Ibogaine; 183
(ee) Lysergic acid diethylamide; 184
(ff) Marijuana or marihuana, except industrial hemp; 185
(gg) Mescaline; 186
(hh) Parahexyl; 187
(ii) Peyote, to include all parts of the plant 188
presently classified botanically as Lophophora williamsii 189
Lemaire, whether growing or not; the seeds thereof; any 190
extract from any part of such plant; and every compound, 191
manufacture, salt, derivative, mixture or preparation of the 192
plant, its seed or extracts; 193
(jj) N-ethyl-3-piperidyl benzilate; 194
(kk) N-methyl-3-piperidyl benzilate; 195
(ll) Psilocybin; 196
(mm) Psilocyn; 197
(nn) Tetrahydrocannabinols naturally contained in a 198
plant of the genus Cannabis (cannabis plant), except 199
industrial hemp, as well as synthetic equivalents o f the 200
substances contained in the cannabis plant, or in the 201
resinous extractives of such plant, or synthetic substances, 202
derivatives and their isomers, or both, with similar 203
chemical structure and pharmacological activity to those 204
substances contained in the plant, such as the following: 205
a. 1 cis or trans tetrahydrocannabinol and their 206
optical isomers; 207
b. 6 cis or trans tetrahydrocannabinol and their 208
optical isomers; 209 SB 763 8
c. 3,4 cis or trans tetrahydrocannabinol and their 210
optical isomers; 211
d. Any compounds of these structures, regardless of 212
numerical designation of atomic positions covered; 213
(oo) Ethylamine analog of phencyclidine; 214
(pp) Pyrrolidine analog of phencyclidine; 215
(qq) Thiophene analog of phencyclidine; 216
(rr) 1-[1-(2-thienyl)cyclohexyl]pyrrolidine; 217
(ss) Salvia divinorum; 218
(tt) Salvinorin A; 219
(uu) Synthetic cannabinoids: 220
a. Any compound structurally derived from 3 -(1- 221
naphthoyl)indole or 1H -indol-3-yl-(1-naphthyl)methane by 222
substitution at the nitrogen atom of the indole ring by 223
alkyl, haloalkyl, alkenyl, cycloalkylmethyl, 224
cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl or 2 -(4- 225
morpholinyl)ethyl group, whether or not further substituted 226
in the indole ring to any extent, wheth er or not substituted 227
in the naphthyl ring to any extent. Including, but not 228
limited to: 229
(i) AM2201, or 1-(5-fluoropentyl)-3-(1- 230
naphthoyl)indole; 231
(ii) JWH-007, or 1-pentyl-2-methyl-3-(1- 232
naphthoyl)indole; 233
(iii) JWH-015, or 1-propyl-2-methyl-3-(1- 234
naphthoyl)indole; 235
(iv) JWH-018, or 1-pentyl-3-(1-naphthoyl)indole; 236
(v) JWH-019, or 1-hexyl-3-(1-naphthoyl)indole; 237
(vi) JWH-073, or 1-butyl-3-(1-naphthoyl)indole; 238
(vii) JWH-081, or 1-pentyl-3-(4-methoxy-1- 239
naphthoyl)indole; 240 SB 763 9
(viii) JWH-098, or 1-pentyl-2-methyl-3-(4-methoxy-1- 241
naphthoyl)indole; 242
(ix) JWH-122, or 1-pentyl-3-(4-methyl-1- 243
naphthoyl)indole; 244
(x) JWH-164, or 1-pentyl-3-(7-methoxy-1- 245
naphthoyl)indole; 246
(xi) JWH-200, or 1-(2-(4-(morpholinyl)ethyl))-3-(1- 247
naphthoyl)indole; 248
(xii) JWH-210, or 1-pentyl-3-(4-ethyl-1- 249
naphthoyl)indole; 250
(xiii) JWH-398, or 1-pentyl-3-(4-chloro-1- 251
naphthoyl)indole; 252
b. Any compound structurally derived from 3 -(1- 253
naphthoyl)pyrrole by substitution at th e nitrogen atom of 254
the pyrrole ring by alkyl, haloalkyl, alkenyl, 255
cycloalkylmethyl, cycloalkylethyl, 1 -(N-methyl-2- 256
piperidinyl)methyl or 2 -(4-morpholinyl)ethyl group, whether 257
or not further substituted in the pyrrole ring to any 258
extent, whether or not substituted in the naphthyl ring to 259
any extent; 260
c. Any compound structurally derived from 1 -(1- 261
naphthylmethyl)indene by substitution at the 3 -position of 262
the indene ring by alkyl, haloalkyl, alkenyl, 263
cycloalkylmethyl, cycloalkylethyl, 1 -(N-methyl-2- 264
piperidinyl)methyl or 2 -(4-morpholinyl)ethyl group, whether 265
or not further substituted in the indene ring to any extent, 266
whether or not substituted in the naphthyl ring to any 267
extent; 268
d. Any compound structurally derived from 3 - 269
phenylacetylindole by substitution at the nitrogen atom of 270
the indole ring with alkyl, haloalkyl, alkenyl, 271
cycloalkylmethyl, cycloalkylethyl, 1 -(N-methyl-2- 272 SB 763 10
piperidinyl)methyl or 2 -(4-morpholinyl)ethyl group, whether 273
or not further substituted in the indole ring to any extent, 274
whether or not substituted in the phenyl ring to any 275
extent. Including, but not limited to: 276
(i) JWH-201, or 1-pentyl-3-(4- 277
methoxyphenylacetyl)indole; 278
(ii) JWH-203, or 1-pentyl-3-(2- 279
chlorophenylacetyl)indole; 280
(iii) JWH-250, or 1-pentyl-3-(2- 281
methoxyphenylacetyl)indole; 282
(iv) JWH-251, or 1-pentyl-3-(2- 283
methylphenylacetyl)indole; 284
(v) RCS-8, or 1-(2-cyclohexylethyl)-3-(2- 285
methoxyphenylacetyl)indole; 286
e. Any compound structurally derived from 2 -(3- 287
hydroxycyclohexyl)phenol by substitution at the 5 -position 288
of the phenolic ring by alkyl, haloalkyl, alkenyl, 289
cycloalkylmethyl, cycloalkylethyl, 1 -(N-methyl-2- 290
piperidinyl)methyl or 2 -(4-morpholinyl)ethyl group, whether 291
or not substituted in the cyclohexyl ring to a ny extent. 292
Including, but not limited to CP 47, 497 and homologues, or 293
2-[(1R,3S)-3-hydroxycyclohexyl]-5-(2-methyloctan-2- 294
yl)phenol, where side chain n=5, and homologues where side 295
chain n-4,6, or 7; 296
f. Any compound containing a 3 -(benzoyl)indole 297
structure with substitution at the nitrogen atom of the 298
indole ring by alkyl, haloalkyl, alkenyl, cycloalkylmethyl, 299
cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl or 2 -(4- 300
morpholinyl)ethyl group, whether or not further substituted 301
in the indole ring to any extent and whether or not 302
substituted in the phenyl ring to any extent. Including, 303
but not limited to: 304 SB 763 11
(i) AM-694, or 1-(5-fluoropentyl)-3-(2- 305
iodobenzoyl)indole; 306
(ii) RCS-4, or 1-pentyl-3-(4-methoxybenzoyl)indole (SR - 307
19 and RCS-4); 308
g. CP 50,556-1, or [(6S,6aR,9R,10aR) -9-hydroxy-6- 309
methyl-3-[(2R)-5-phenylpentan-2-yl] oxy-5,6,6a,7,8,9,10,10a- 310
octahydrophenanthridin -1-yl] acetate; 311
h. HU-210, or (6aR,10aR)-9-(hydroxymethyl)-6,6- 312
dimethyl-3-(2-methyloctan-2-yl)-6a,7,10,10a- 313
tetrahydrobenzo[c]chromen -1-ol; 314
i. HU-211, or Dexanabinol,(6aS,10aS) -9-(hydroxymethyl)- 315
6,6-dimethyl-3-(2-methyloctan-2-yl)-6a,7,10,10a- 316
tetrahydrobenzo[c]chromen -1-ol; 317
j. Dimethylheptylpyran, or DMHP; 318
(6) Any material, compound, mixtur e or preparation 319
containing any quantity of the following substances having a 320
depressant effect on the central nervous system, including 321
their salts, isomers and salts of isomers whenever the 322
existence of these salts, isomers and salts of isomers is 323
possible within the specific chemical designation: 324
(a) Gamma-hydroxybutyric acid; 325
(b) Mecloqualone; 326
(c) Methaqualone; 327
(7) Any material, compound, mixture or preparation 328
containing any quantity of the following substances having a 329
stimulant effect on the central nervous system, including 330
their salts, isomers and salts of isomers: 331
(a) Aminorex; 332
(b) N-benzylpiperazine; 333
(c) Cathinone; 334
(d) Fenethylline; 335
(e) 3-Fluoromethcathinone; 336 SB 763 12
(f) 4-Fluoromethcathinone; 337
(g) Mephedrone, or 4-methylmethcathinone; 338
(h) Methcathinone; 339
(i) 4-methoxymethcathinone; 340
(j) (+,-)cis-4-methylaminorex ((+,-)cis-4,5-dihydro-4- 341
methyl-5-phenyl-2-oxazolamine); 342
(k) Methylenedioxypyrovalerone, MDPV, or 1 -(1,3- 343
Benzodioxol-5-yl)-2-(1-pyrrolidinyl)-1-pentanone; 344
(l) Methylone, or 3,4-Methylenedioxymethcathinone; 345
(m) 4-Methyl-alpha-pyrrolidinobutiophenone, or MPBP; 346
(n) N-ethylamphetamine; 347
(o) N,N-dimethylamphetamine; 348
(p) Quinolin-8-yl 1-pentyl-1H-indole-3-carboxylate (PB- 349
22; QUPIC); 350
(q) Quinolin-8-yl 1-(5-fluoropentyl)-1H-indole-3- 351
carboxylate (5-fluoro-PB-22; 5F-PB-22); 352
(r) N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(4- 353
fluorobenzyl)-1H-indazole-3-carboxamide (AB-FUBINACA); 354
(s) N-(1-amino-3, 3-dimethyl-1-oxobutan-2-yl)-1-pentyl- 355
1H-indazole-3-carboxamide (ADB-PINACA); 356
(8) A temporary listing of substances subject to 357
emergency scheduling under federal law shall include any 358
material, compound, mixture or prepara tion which contains 359
any quantity of the following substances: 360
(a) (1-pentyl-1H-indol-3-yl)(2,2,3,3- 361
tetramethylcyclopropyl)methanone, its optical, positional, 362
and geometric isomers, salts, and salts of isomers; 363
(b) [1-(5-fluoro-pentyl)-1H-indol-3-yl](2,2,3,3- 364
tetramethylcyclopropyl)methanone, its optical, positional, 365
and geometric isomers, salts, and salts of isomers; 366 SB 763 13
(c) N-(1-adamantyl)-1-pentyl-1H-indazole-3- 367
carboxamide, its optical, positional, and geometric isomers, 368
salts, and salts of isomers; 369
(d) 2-(4-iodo-2,5-dimethoxyphenyl)-N-(2- 370
methoxybenzyl)ethanamine, its optical, positional, and 371
geometric isomers, salts, and salts of isomers; 372
(e) 2-(4-chloro-2,5-dimethoxyphenyl)-N-(2- 373
methoxybenzyl)ethanamine, its optical, po sitional, and 374
geometric isomers, salts, and salts of isomers; 375
(f) 2-(4-bromo-2,5-dimethoxyphenyl)-N-(2- 376
methoxybenzyl)ethanamine, its optical, positional, and 377
geometric isomers, salts, and salts of isomers; 378
(g) 4-methyl-N-ethylcathinone, its optical, 379
positional, and geometric isomers, salts, and salts of 380
isomers; 381
(h) 4-methyl-alpha-pyrrolidinopropiophenone, its 382
optical, positional, and geometric isomers, salts, and salts 383
of isomers; 384
(i) Alpha-pyrrolidinopentiophenone, its optic al, 385
positional, and geometric isomers, salts, and salts of 386
isomers; 387
(j) Butylone, its optical, positional, and geometric 388
isomers, salts, and salts of isomers; 389
(k) Pentedrone, its optical, positional, and geometric 390
isomers, salts, and salts of isomers; 391
(l) Pentylone, its optical, positional, and geometric 392
isomers, salts, and salts of isomers; 393
(m) Naphyrone, its optical, positional, and geometric 394
isomers, salts, and salts of isomers; 395
(n) Alpha-pyrrolidinobutiophenone, its o ptical, 396
positional, and geometric isomers, salts, and salts of 397
isomers; 398 SB 763 14
(o) N-(1-amino-3-methyl-1-oxobutan-2-yl)-1- 399
(cyclohexylmethyl)-1H-indazole-3-carboxamide, its optical, 400
positional, and geometric isomers, salts, and salts of 401
isomers; 402
(p) N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-pentyl-1H- 403
indazole-3-carboxamide, its optical, positional, and 404
geometric isomers, salts, and salts of isomers; 405
(q) [1-(5-fluoropentyl)-1H-indazole-3-yl](naphthalen-1- 406
yl)methanone, its optical, positional, and geometric 407
isomers, salts, and salts of isomers; 408
(r) N-[1-[2-hydroxy-2-(thiophen-2-yl) ethyl]piperidin- 409
4-yl]-N-phenylpropionamide, its isomers, esters, ethers, 410
salts, and salts of isomers, esters, and ethers; 411
(s) N-(1-phenethylpiperidin-4-yl)-N-phenylacetamide, 412
its optical, positional, and geometric isomers, salts, and 413
salts of isomers; 414
(t) N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1- 415
(cyclohexylmethyl)-1H-indazole-3-carboxamide, its optical, 416
positional, and geometric isomers, salt s, and salts of 417
isomers; 418
(u) methyl 2-(1-(5-fluoropentyl)-1H-indazole-3- 419
carboxamido)-3,3-dimethylbutanoate, its optical, positional, 420
and geometric isomers, salts, and salts of isomers; 421
(v) methyl 2-(1-(5-fluoropentyl)-1H-indazole-3- 422
carboxamido)-3-methylbutanoate, its optical, positional, and 423
geometric isomers, salts, and salts of isomers; 424
(w) N-(adamantan-1-yl)-1-(5-fluoropentyl)-1H-indazole- 425
3-carboxamide, its optical, positional, and geometric 426
isomers, salts, and salts of isomers; 427
(x) N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(4- 428
fluorobenzyl)-1H-indazole-3-carboxamide, its optical, 429 SB 763 15
positional, and geometric isomers, salts, and salts of 430
isomers; 431
(y) methyl 2-(1-(cyclohexylmethyl)-1H-indole-3- 432
carboxamido)-3,3-dimethylbutanoate, its optical, positional, 433
and geometric isomers, salts, and salts of isomers; 434
(z) methyl 2-(1-(4-fluorobenzyl)-1H-indazole-3- 435
carboxamido)-3,3-dimethylbutanoate, its optical, positional, 436
and geometric isomers, salts, and salts of isomers; 437
(aa) N-(2-fluorophenyl)-N-(1-phenethylpiperidin-4- 438
yl)propionamide, its isomers, esters, ethers, salts, and 439
salts of isomers, esters, and ethers; 440
(bb) methyl 2-(1-(4-fluorobenzyl)-1H-indazole-3- 441
carboxamido)-3-methylbutanoate, its optical, po sitional, and 442
geometric isomers, salts, and salts of isomers; 443
(cc) N-(1-phenethylpiperidin-4-yl)-N- 444
phenylcyclopropanecarboxamide, its isomers, esters, ethers, 445
salts, and salts of isomers, esters, and ethers; 446
(dd) N-(1-phenethylpiperidin-4-yl)-N- 447
phenylpentanamide, its isomers, esters, ethers, salts, and 448
salts of isomers, esters, and ethers; 449
(ee) N-(4-fluorophenyl)-N-(1-phenethylpiperidin-4- 450
yl)butyramide, its isomers, esters, ethers, salts, and salts 451
of isomers, esters, and ethers; 452
(ff) N-(4-methoxyphenyl)-N-(1-phenethylpiperidin-4- 453
yl)butyramide, its isomers, esters, ethers, salts, and salts 454
of isomers, esters, and ethers; 455
(gg) N-(4-chlorophenyl)-N-(1-phenethylpiperidin-4- 456
yl)isobutyramide, its isomers, esters, ethers, sa lts, and 457
salts of isomers, esters, and ethers; 458
(hh) N-(1-phenethylpiperidin-4-yl)-N- 459
phenylisobutyramide, its isomers, esters, ethers, salts, and 460
salts of isomers, esters, and ethers; 461 SB 763 16
(ii) N-(1-phenethylpiperidin-4-yl)-N- 462
phenylcyclopentaneca rboxamide, its isomers, esters, ethers, 463
salts, and salts of isomers, esters, and ethers; 464
(jj) Fentanyl-related substances, their isomers, 465
esters, ethers, salts, and salts of isomers, esters, and 466
ethers. Fentanyl-related substance shall mean any s ubstance 467
not otherwise listed under another Drug Enforcement 468
Administration Controlled Substance Code Number, and for 469
which no exemption or approval is in effect under section 470
505 of the Federal Food, Drug, and Cosmetic Act, 21 U.S.C. 471
Section 355, that is structurally related to fentanyl by one 472
or more of the following modifications: 473
a. Replacement of the phenyl portion of the phenethyl 474
group by any monocycle, whether or not further substituted 475
in or on the monocycle; 476
b. Substitution in or on the phenethyl group with 477
alkyl, alkenyl, alkoxyl, hydroxyl, halo, haloalkyl, amino or 478
nitro groups; 479
c. Substitution in or on the piperidine ring with 480
alkyl, alkenyl, alkoxyl, ester, ether, hydroxyl, amino or 481
nitro groups; 482
d. Replacement of the aniline ring with any aromatic 483
monocycle, whether or not further substituted in or on the 484
aromatic monocycle; or 485
e. Replacement of the N -propionyl group by another 486
acyl group; 487
(kk) Naphthalen-1-yl 1-(5-fluoropentyl)-1H-indole-3- 488
carboxylate, its optical, positional, and geometric isomers, 489
salts, and salts of isomers (NM2201; CBL2201); 490
(ll) N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(5- 491
fluoropentyl)-1H-indazole-3-carboxamide, its optical, 492 SB 763 17
positional, and geometric isomers, salts , and salts of 493
isomers (5F-AB-PINACA); 494
(mm) 1-(4-cyanobutyl)-N-(2-phenylpropan-2-yl)-1H- 495
indazole-3-carboxamide, its optical, positional, and 496
geometric isomers, salts, and salts of isomers (4 -CN-CUMYL- 497
BUTINACA; 4-cyano-CUMYL-BUTINACA; 4-CN-CUMYLBINACA; CUMYL- 498
4CN-BINACA; SGT-78); 499
(nn) methyl 2-(1-(cyclohexylmethyl)-1H-indole-3- 500
carboxamido)-3-methylbutanoate, its optical, positional, and 501
geometric isomers, salts, and salts of isomers (MMB -CHMICA, 502
AMB-CHMICA); 503
(oo) 1-(5-fluoropentyl)-N-(2-phenylpropan-2-yl)-1H- 504
pyrrolo[2,3-b]pyridine-3-carboxamide, its optical, 505
positional, and geometric isomers, salts, and salts of 506
isomers (5F-CUMYL-P7AICA); 507
(pp) N-ethylpentylone, its optical, positional, and 508
geometric isomers, salts, and salts of isomers (ephylone, 1 - 509
(1,3-benzodioxol-5-yl)-2-(ethylamino)-pentan-1-one; 510
(qq) ethyl 2-(1-(5-fluoropentyl)-1H-indazole-3- 511
carboxamido)-3,3-dimethylbutanoate, its optical, positional, 512
and geometric isomers, salts, and salts of isomers (trivial 513
name: 5F-EDMB-PINACA); 514
(rr) methyl 2-(1-(5-fluoropentyl)-1H-indole-3- 515
carboxamido)-3,3-dimethylbutanoate, its optical, positional, 516
and geometric isomers, salts, and salts of isomers (trivial 517
name: 5F-MDMB-PICA); 518
(ss) N-(adamantan-1-yl)-1-(4-fluorobenzyl)-1H-indazole- 519
3-carboxamide, its optical, positional, and geometric 520
isomers, salts, and salts of isomers (trivial names: FUB - 521
AKB48; FUB-APINACA; AKB48 N-(4-FLUOROBENZYL)); 522
(tt) 1-(5-fluoropentyl)-N-(2-phenylpropan-2-yl)-1H- 523
indazole-3-carboxamide, its optical, positional, and 524 SB 763 18
geometric isomers, salts, and salts of isomers (trivial 525
names: 5F-CUMYL-PINACA; SGT-25); 526
(uu) (1-(4-fluorobenzyl)-1H-indol-3-yl)(2,2,3,3- 527
tetramethylcyclopropyl) methanone, its optical, positional, 528
and geometric isomers, salts, and salts of isomers (trivial 529
name: FUB-144); 530
(vv) N-ethylhexedrone, its optical, positional, and 531
geometric isomers, salts, and salts of isomers (Other name: 532
2-(ethylamino)-1-phenylhexan-1-one); 533
(ww) alpha-pyrrolidinohexanophenone, its optical, 534
positional, and geometric isomers, salts, and salts of 535
isomers (Other names: α -PHP; alpha-pyrrolidinohexiophenone; 536
1-phenyl-2-(pyrrolidin-1-yl)hexan-1-one); 537
(xx) 4-methyl-alpha-ethylaminopentiophenone, its 538
optical, positional, and geometric isomers, salts, and salts 539
of isomers; (Other names: 4 -MEAP; 2-(ethylamino)-1-(4- 540
methylphenyl)pentan-1-one); 541
(yy) 4'-methyl-alpha-pyrrolidinohexiophenone, its 542
optical, positional, and geometric isomers, salts, and salts 543
of isomers (Other names: MPHP; 4' -methyl-alpha- 544
pyrrolidinohexanophenone; 1 -(4-methylphenyl)-2-(pyrrolidin-1- 545
yl)hexan-1-one); 546
(zz) alpha-pyrrolidinoheptaphenone, its optical, 547
positional, and geometric isomers, salts, and salts of 548
isomers (Other names: PV 8; 1-phenyl-2-(pyrrolidin-1- 549
yl)heptan-1-one); 550
(aaa) 4'-chloro-alpha-pyrrolidinovalerophenone, its 551
optical, positional, and geometric isomers, salts, and salts 552
of isomers (Other names: 4 -chloro-α-PVP; 4'-chloro-alpha- 553
pyrrolidinopentiophenone; 1 -(4-chlorophenyl)-2-(pyrrolidin-1- 554
yl)pentan-1-one); 555 SB 763 19
(9) Khat, to include all parts of the plant presently 556
classified botanically as catha edulis, whether growing or 557
not; the seeds thereof; any extract from any part of such 558
plant; and every compound, manufacture, salt, derivative, 559
mixture, or preparation of the plant, its seed or extracts. 560
3. The department of health and senior services shall 561
place a substance in Schedule II if it finds that: 562
(1) The substance has high potential for abus e; 563
(2) The substance has currently accepted medical use 564
in treatment in the United States, or currently accepted 565
medical use with severe restrictions; and 566
(3) The abuse of the substance may lead to severe 567
psychic or physical dependence. 568
4. The controlled substances listed in this subsection 569
are included in Schedule II: 570
(1) Any of the following substances whether produced 571
directly or indirectly by extraction from substances of 572
vegetable origin, or independently by means of chemi cal 573
synthesis, or by combination of extraction and chemical 574
synthesis: 575
(a) Opium and opiate; and any salt, compound, 576
derivative or preparation of opium or opiate, excluding 577
apomorphine, thebaine -derived butorphanol, dextrorphan, 578
nalbuphine, nalmefene, naloxegol, naloxone, and naltrexone, 579
and their respective salts, but including the following: 580
a. Raw opium; 581
b. Opium extracts; 582
c. Opium fluid; 583
d. Powdered opium; 584
e. Granulated opium; 585
f. Tincture of opium; 586
g. Codeine; 587 SB 763 20
h. Dihydroetorphine; 588
i. Ethylmorphine; 589
j. Etorphine hydrochloride; 590
k. Hydrocodone; 591
l. Hydromorphone; 592
m. Metopon; 593
n. Morphine; 594
o. Oripavine; 595
p. Oxycodone; 596
q. Oxymorphone; 597
r. Thebaine; 598
(b) Any salt, compound, derivative, or preparation 599
thereof which is chemically equivalent or identical with any 600
of the substances referred to in this subdivision, but not 601
including the isoquinoline alkaloids of opium; 602
(c) Opium poppy and poppy straw; 603
(d) Coca leaves and any salt, compound, derivative, or 604
preparation of coca leaves, and any salt, compound, 605
derivative, or preparation thereof which is chemically 606
equivalent or identical with any of these substances, but 607
not including the following: 608
a. Decocainized coca leaves or extractions of coca 609
leaves, which extractions do not contain cocaine or 610
ecgonine; or 611
b. Ioflupane; 612
(e) Concentrate of poppy straw (the crude extract of 613
poppy straw in either liquid, solid or powder form which 614
contains the phenanthrene alkaloids of the opium poppy); 615
(2) Any of the following opiates, including their 616
isomers, esters, ethers, salts, and salts of isomers, 617
whenever the existence of these isomers, esters, ethers, and 618 SB 763 21
salts is possible within the specific chemical designation, 619
dextrorphan and levopropoxyphene excepted: 620
(a) Alfentanil; 621
(b) Alphaprodine; 622
(c) Anileridine; 623
(d) Bezitramide; 624
(e) Bulk dextropropoxyphene; 625
(f) Carfentanil; 626
(g) Dihydrocodeine; 627
(h) Diphenoxylate; 628
(i) Fentanyl; 629
(j) Isomethadone; 630
(k) Levo-alphacetylmethadol; 631
(l) Levomethorphan; 632
(m) Levorphanol; 633
(n) Metazocine; 634
(o) Methadone; 635
(p) Methadone-Intermediate, 4-cyano-2-dimethylamino-4, 636
4-diphenylbutane; 637
(q) Moramide-Intermediate, 2-methyl-3-morpholino-1, 1- 638
diphenylpropane-carboxylic acid; 639
(r) Pethidine (meperidine); 640
(s) Pethidine-Intermediate-A, 4-cyano-1-methyl-4- 641
phenylpiperidine; 642
(t) Pethidine-Intermediate-B, ethyl-4-phenylpiperidine- 643
4-carboxylate; 644
(u) Pethidine-Intermediate-C, 1-methyl-4- 645
phenylpiperdine-4-carboxylic acid; 646
(v) Phenazocine; 647
(w) Piminodine; 648
(x) Racemethorphan; 649
(y) Racemorphan; 650 SB 763 22
(z) Remifentanil; 651
(aa) Sufentanil; 652
(bb) Tapentadol; 653
(cc) Thiafentanil; 654
(3) Any material, compound, mixture, or preparation 655
which contains any quantity of the following substances 656
having a stimulant effect on the central nervous system: 657
(a) Amphetamine, its salts, optical isomers, and salts 658
of its optical isomers; 659
(b) Lisdexamfetamine, its salts, isomers, and salts of 660
its isomers; 661
(c) Methamphetamine, its salts, isomers, and salts of 662
its isomers; 663
(d) Phenmetrazine and its salts; 664
(e) Methylphenidate; 665
(4) Any material, compound, mixture, or preparation 666
which contains any quantity of the following substances 667
having a depressant effect on the central nervous system, 668
including its salts, isomers, and salt s of isomers whenever 669
the existence of those salts, isomers, and salts of isomers 670
is possible within the specific chemical designation: 671
(a) Amobarbital; 672
(b) Glutethimide; 673
(c) Pentobarbital; 674
(d) Phencyclidine; 675
(e) Secobarbital; 676
(5) Hallucinogenic substances: 677
(a) Any material or compound which contains any 678
quantity of nabilone; 679
(b) Dronabinol [(-)-Δ-9-trans tetrahydrocannabinol] in 680
an oral solution in a drug product approved for marketing by 681
the U.S. Food and Drug Administration; 682 SB 763 23
(6) Any material, compound, mixture, or preparation 683
which contains any quantity of the following substances: 684
(a) Immediate precursor to amphetamine and 685
methamphetamine: Phenylacetone; 686
(b) Immediate precursors to phencyclidine (PCP): 687
a. 1-phenylcyclohexylamine; 688
b. 1-piperidinocyclohexanecarbonitrile (PCC); 689
(c) Immediate precursor to fentanyl: 4 -anilino-N- 690
phenethyl-4-piperidine (ANPP); 691
(7) Any material, compound, mixture, or preparation 692
which contains any quantity of the following alkyl nitrites: 693
(a) Amyl nitrite; 694
(b) Butyl nitrite. 695
5. The department of health and senior services shall 696
place a substance in Schedule III if it finds that: 697
(1) The substance has a potent ial for abuse less than 698
the substances listed in Schedules I and II; 699
(2) The substance has currently accepted medical use 700
in treatment in the United States; and 701
(3) Abuse of the substance may lead to moderate or low 702
physical dependence or hi gh psychological dependence. 703
6. The controlled substances listed in this subsection 704
are included in Schedule III: 705
(1) Any material, compound, mixture, or preparation 706
which contains any quantity of the following substances 707
having a potential for abuse associated with a stimulant 708
effect on the central nervous system: 709
(a) Benzphetamine; 710
(b) Chlorphentermine; 711
(c) Clortermine; 712
(d) Phendimetrazine; 713 SB 763 24
(2) Any material, compound, mixture or preparation 714
which contains any quantity or salt of the following 715
substances or salts having a depressant effect on the 716
central nervous system: 717
(a) Any material, compound, mixture or preparation 718
which contains any quantity or salt of the following 719
substances combined with one or more active medicinal 720
ingredients: 721
a. Amobarbital; 722
b. Secobarbital; 723
c. Pentobarbital; 724
(b) Any suppository dosage form containing any 725
quantity or salt of the following: 726
a. Amobarbital; 727
b. Secobarbital; 728
c. Pentobarbital; 729
(c) Any substance which contains any quantity of a 730
derivative of barbituric acid or its salt; 731
(d) Chlorhexadol; 732
(e) Embutramide; 733
(f) Gamma hydroxybutyric acid and its salts, isomers, 734
and salts of isomers contained in a d rug product for which 735
an application has been approved under Section 505 of the 736
federal Food, Drug, and Cosmetic Act; 737
(g) Ketamine, its salts, isomers, and salts of isomers; 738
(h) Lysergic acid; 739
(i) Lysergic acid amide; 740
(j) Methyprylon; 741
(k) Perampanel, and its salts, isomers, and salts of 742
isomers; 743
(l) Sulfondiethylmethane; 744
(m) Sulfonethylmethane; 745 SB 763 25
(n) Sulfonmethane; 746
(o) Tiletamine and zolazepam or any salt thereof; 747
(3) Nalorphine; 748
(4) Any material, compound, mixture, or preparation 749
containing limited quantities of any of the following 750
narcotic drugs or their salts: 751
(a) Not more than 1.8 grams of codeine per one hundred 752
milliliters or not more than ninety milligrams per dosage 753
unit, with an equal or greater quantity of an isoquinoline 754
alkaloid of opium; 755
(b) Not more than 1.8 grams of codeine per one hundred 756
milliliters or not more than ninety milligrams per dosage 757
unit with one or more active, nonnarcotic ingredients in 758
recognized therapeutic amounts; 759
(c) Not more than 1.8 grams of dihydrocodeine per one 760
hundred milliliters or not more than ninety milligrams per 761
dosage unit, with one or more active, nonnarcotic 762
ingredients in recognized therapeutic amounts; 763
(d) Not more than three hundred milligrams of 764
ethylmorphine per one hundred milliliters or not more than 765
fifteen milligrams per dosage unit, with one or more active, 766
nonnarcotic ingredients in recognized therapeutic amounts; 767
(e) Not more than five hun dred milligrams of opium per 768
one hundred milliliters or per one hundred grams or not more 769
than twenty-five milligrams per dosage unit, with one or 770
more active nonnarcotic ingredients in recognized 771
therapeutic amounts; 772
(f) Not more than fifty mill igrams of morphine per one 773
hundred milliliters or per one hundred grams, with one or 774
more active, nonnarcotic ingredients in recognized 775
therapeutic amounts; 776 SB 763 26
(5) Any material, compound, mixture, or preparation 777
containing any of the following narco tic drugs or their 778
salts: Buprenorphine; 779
(6) Anabolic steroids. Any drug or hormonal 780
substance, chemically and pharmacologically related to 781
testosterone (other than estrogens, progestins, 782
corticosteroids, and dehydroepiandrosterone) that promot es 783
muscle growth, except an anabolic steroid which is expressly 784
intended for administration through implants to cattle or 785
other nonhuman species and which has been approved by the 786
Secretary of Health and Human Services for that 787
administration. If any person prescribes, dispenses, or 788
distributes such steroid for human use, such person shall be 789
considered to have prescribed, dispensed, or distributed an 790
anabolic steroid within the meaning of this subdivision. 791
Unless specifically excepted or unless listed in another 792
schedule, any material, compound, mixture or preparation 793
containing any quantity of the following substances, 794
including its salts, esters and ethers: 795
(a) 3ß,17ß-dihydroxy-5α-androstane; 796
(b) 3α,17β-dihydroxy-5α-androstane; 797
(c) 5α-androstan-3,17-dione; 798
(d) 1-androstenediol (3β,17β -dihydroxy-5α-androst-1- 799
ene); 800
(e) 1-androstenediol (3α,17β -dihydroxy-5α-androst-1- 801
ene); 802
(f) 4-androstenediol (3β,17β -dihydroxy-androst-4-ene); 803
(g) 5-androstenediol (3β,17β-dihydroxy-androst-5-ene); 804
(h) 1-androstenedione ([5α] -androst-1-en-3,17-dione); 805
(i) 4-androstenedione (androst -4-en-3,17-dione); 806
(j) 5-androstenedione (androst -5-en-3,17-dione); 807 SB 763 27
(k) Bolasterone (7α, 17α -dimethyl-17β-hydroxyandrost-4- 808
en-3-one); 809
(l) Boldenone (17β-hydroxyandrost-1,4,-diene-3-one); 810
(m) Boldione; 811
(n) Calusterone (7β, 17α -dimethyl-17β-hydroxyandrost-4- 812
en-3-one); 813
(o) Clostebol (4-chloro-17β-hydroxyandrost-4-en-3-one); 814
(p) Dehydrochloromethyltestosterone (4-chloro-17β- 815
hydroxy-17α-methyl-androst-1,4-dien-3-one); 816
(q) Desoxymethyltestosterone; 817
(r) 4-dihydrotestosterone (17ß -hydroxy-androstan-3- 818
one); 819
(s) Drostanolone (17ß-hydroxy-2α-methyl-5α-androstan-3- 820
one); 821
(t) Ethylestrenol (17α-ethyl-17ß-hydroxyestr-4-ene); 822
(u) Fluoxymesterone (9-fluoro-17α-methyl-11ß,17ß- 823
dihydroxyandrost-4-en-3-one); 824
(v) Formebolone (2-formyl-17α-methyl-11α,17ß- 825
dihydroxyandrost-1,4-dien-3-one); 826
(w) Furazabol (17α-methyl-17ß-hydroxyandrostano[2,3 -c]- 827
furazan); 828
(x) 13ß-ethyl-17ß-hydroxygon-4-en-3-one; 829
(y) 4-hydroxytestosterone (4,17ß -dihydroxy-androst-4- 830
en-3-one); 831
(z) 4-hydroxy-19-nortestosterone (4,17ß -dihydroxy-estr- 832
4-en-3-one); 833
(aa) Mestanolone (17α-methyl-17ß-hydroxy-5α-androstan- 834
3-one); 835
(bb) Mesterolone (1α- methyl-17ß-hydroxy-[5α]- 836
androstan-3-one); 837
(cc) Methandienone (17α-methyl-17ß-hydroxyandrost-1,4- 838
dien-3-one); 839 SB 763 28
(dd) Methandriol (17α-methyl-3ß,17ß-dihydroxyandrost-5- 840
ene); 841
(ee) Methasterone (2α,17α -dimethyl-5α-androstan-17β-ol- 842
3-one); 843
(ff) Methenolone (1-methyl-17ß-hydroxy-5α-androst-1-en- 844
3-one); 845
(gg) 17α-methyl-3β,17β-dihydroxy-5α-androstane; 846
(hh) 17α-methyl-3α,17β-dihydroxy-5α-androstane; 847
(ii) 17α-methyl-3β,17β-dihydroxyandrost-4-ene; 848
(jj) 17α-methyl-4-hydroxynandrolone (17α -methyl-4- 849
hydroxy-17β-hydroxyestr-4-en-3-one); 850
(kk) Methyldienolone (17α -methyl-17β-hydroxyestra- 851
4,9(10)-dien-3-one); 852
(ll) Methyltrienolone (17α -methyl-17β-hydroxyestra- 853
4,9,11-trien-3-one); 854
(mm) Methyltestosterone (17α -methyl-17β-hydroxyandrost- 855
4-en-3-one); 856
(nn) Mibolerone (7α,17α-dimethyl-17β-hydroxyestr-4-en- 857
3-one); 858
(oo) 17α-methyl-Δ1-dihydrotestosterone (17β -hydroxy- 859
17α-methyl-5α-androst-1-en-3-one) (a.k.a. '17-α-methyl-1- 860
testosterone'); 861
(pp) Nandrolone (17β-hydroxyestr-4-ene-3-one); 862
(qq) 19-nor-4-androstenediol (3β,17β -dihydroxyestr-4- 863
ene); 864
(rr) 19-nor-4-androstenediol (3α,17β -dihydroxyestr-4- 865
ene); 866
(ss) 19-nor-4,9(10)-androstadienedione (estra -4,9(10)- 867
diene-3,17-dione); 868
(tt) 19-nor-5-androstenediol (3β,17β -dihydroxyestr-5- 869
ene); 870 SB 763 29
(uu) 19-nor-5-androstenediol (3α,17β -dihydroxyestr-5- 871
ene); 872
(vv) 19-nor-4-androstenedione (estr -4-en-3,17-dione); 873
(ww) 19-nor-5-androstenedione (estr -5-en-3,17-dione); 874
(xx) Norbolethone (13β,17α -diethyl-17β-hydroxygon-4-en- 875
3-one); 876
(yy) Norclostebol (4-chloro-17β-hydroxyestr-4-en-3- 877
one); 878
(zz) Norethandrolone (17α -ethyl-17β-hydroxyestr-4-en-3- 879
one); 880
(aaa) Normethandrolone (17α -methyl-17β-hydroxyestr-4- 881
en-3-one); 882
(bbb) Oxandrolone (17α-methyl-17β-hydroxy-2-oxa-[5α]- 883
androstan-3-one); 884
(ccc) Oxymesterone (17α-methyl-4,17β-dihydroxyandrost- 885
4-en-3-one); 886
(ddd) metholone (17α-methyl-2-hydroxymethylene-17β- 887
hydroxy-[5α]-androstan-3-one); 888
(eee) Prostanozol (17β-hydroxy-5α-androstano[3,2- 889
c]pyrazole); 890
(fff) Stanolone (Δ1-dihydrotestosterone (a.k.a. 1 - 891
testosterone)(17β-hydroxy-5α-androst-1-en-3-one)); 892
(ggg) Stanozolol (17α-methyl-17ß-hydroxy-[5α]-androst- 893
2-eno[3,2-c]-pyrazole); 894
(hhh) Stenbolone (17ß-hydroxy-2-methyl-[5α]-androst-1- 895
en-3-one); 896
(iii) Testolactone (13-hydroxy-3-oxo-13,17- 897
secoandrosta-1,4-dien-17-oic acid lactone); 898
(jjj) Testosterone (17ß-hydroxyandrost-4-en-3-one); 899
(kkk) Tetrahydrogestrinone (13ß,17α -diethyl-17ß- 900
hydroxygon-4,9,11-trien-3-one); 901
(lll) Trenbolone (17ß-hydroxyestr-4,9,11-trien-3-one); 902 SB 763 30
(mmm) Any salt, ester, or ether of a drug or substance 903
described or listed in this subdivision, except an anabolic 904
steroid which is expressly intended for administration 905
through implants to cattle or other nonhuman species and 906
which has been approved by the Secretary of Health and Human 907
Services for that admini stration; 908
(7) Dronabinol (synthetic) in sesame oil and 909
encapsulated in a soft gelatin capsule in a United States 910
Food and Drug Administration approved drug product; 911
(8) The department of health and senior services may 912
except by rule any comp ound, mixture, or preparation 913
containing any stimulant or depressant substance listed in 914
subdivisions (1) and (2) of this subsection from the 915
application of all or any part of sections 195.010 to 916
195.320 if the compound, mixture, or preparation contain s 917
one or more active medicinal ingredients not having a 918
stimulant or depressant effect on the central nervous 919
system, and if the admixtures are included therein in 920
combinations, quantity, proportion, or concentration that 921
vitiate the potential for abu se of the substances which have 922
a stimulant or depressant effect on the central nervous 923
system. 924
7. The department of health and senior services shall 925
place a substance in Schedule IV if it finds that: 926
(1) The substance has a low potential fo r abuse 927
relative to substances in Schedule III; 928
(2) The substance has currently accepted medical use 929
in treatment in the United States; and 930
(3) Abuse of the substance may lead to limited 931
physical dependence or psychological dependence relati ve to 932
the substances in Schedule III. 933 SB 763 31
8. The controlled substances listed in this subsection 934
are included in Schedule IV: 935
(1) Any material, compound, mixture, or preparation 936
containing any of the following narcotic drugs or their 937
salts calculated as the free anhydrous base or alkaloid, in 938
limited quantities as set forth below: 939
(a) Not more than one milligram of difenoxin and not 940
less than twenty-five micrograms of atropine sulfate per 941
dosage unit; 942
(b) Dextropropoxyphene (alpha -(+)-4-dimethylamino-1, 2- 943
diphenyl-3-methyl-2-propionoxybutane); 944
(c) 2-[(dimethylamino)methyl] -1-(3- 945
methoxyphenyl)cyclohexanol, its salts, optical and geometric 946
isomers, and salts of these isomers (including tramadol); 947
(d) Any of the following limited quantities of 948
narcotic drugs or their salts, which shall include one or 949
more nonnarcotic active medicinal ingredients in sufficient 950
proportion to confer upon the compound, mixture or 951
preparation valuable medicinal qualities other than those 952
possessed by the narcotic drug alone: 953
a. Not more than two hundred milligrams of codeine per 954
one hundred milliliters or per one hundred grams; 955
b. Not more than one hundred milligrams of 956
dihydrocodeine per one hundred milliliters or per one 957
hundred grams; 958
c. Not more than one hundred milligrams of 959
ethylmorphine per one hundred milliliters or per one hundred 960
grams; 961
(2) Any material, compound, mixture or preparation 962
containing any quantity of the following substances, 963
including their salts, isomers, and salts of isomers 964 SB 763 32
whenever the existence of those salts, isomers, and salts of 965
isomers is possible within the specific chemical designation: 966
(a) Alfaxalone; 967
(b) Alprazolam; 968
(c) Barbital; 969
(d) Bromazepam; 970
(e) Camazepam; 971
(f) Carisoprodol; 972
(g) Chloral betaine; 973
(h) Chloral hydrate; 974
(i) Chlordiazepoxide; 975
(j) Clobazam; 976
(k) Clonazepam; 977
(l) Clorazepate; 978
(m) Clotiazepam; 979
(n) Cloxazolam; 980
(o) Delorazepam; 981
(p) Diazepam; 982
(q) Dichloralphenazone; 983
(r) Estazolam; 984
(s) Ethchlorvynol; 985
(t) Ethinamate; 986
(u) Ethyl loflazepate; 987
(v) Fludiazepam; 988
(w) Flunitrazepam; 989
(x) Flurazepam; 990
(y) Fospropofol; 991
(z) Halazepam; 992
(aa) Haloxazolam; 993
(bb) Ketazolam; 994
(cc) Loprazolam; 995
(dd) Lorazepam; 996 SB 763 33
(ee) Lormetazepam; 997
(ff) Mebutamate; 998
(gg) Medazepam; 999
(hh) Meprobamate; 1000
(ii) Methohexital; 1001
(jj) Methylphenobarbital (mephoba rbital); 1002
(kk) Midazolam; 1003
(ll) Mifepristone; 1004
(mm) Nimetazepam; 1005
[(mm)] (nn) Nitrazepam; 1006
[(nn)] (oo) Nordiazepam; 1007
[(oo)] (pp) Oxazepam; 1008
[(pp)] (qq) Oxazolam; 1009
[(qq)] (rr) Paraldehyde; 1010
[(rr)] (ss) Petrichloral; 1011
[(ss)] (tt) Phenobarbital; 1012
[(tt)] (uu) Pinazepam; 1013
[(uu)] (vv) Prazepam; 1014
[(vv)] (ww) Quazepam; 1015
[(ww)] (xx) Suvorexant; 1016
[(xx)] (yy) Temazepam; 1017
[(yy)] (zz) Tetrazepam; 1018
[(zz)] (aaa) Triazolam; 1019
[(aaa)] (bbb) Zaleplon; 1020
[(bbb)] (ccc) Zolpidem; 1021
[(ccc)] (ddd) Zopiclone; 1022
(3) Any material, compound, mixture, or preparation 1023
which contains any quantity of the following substance 1024
including its salts, isomers and salts of isomers whenever 1025
the existence of such salts, isomers and salts of isomers is 1026
possible: fenfluramine; 1027 SB 763 34
(4) Any material, compound, mixture, or preparation 1028
which contains any quantity of the following substances, 1029
including its salts, isomers, and salts of isomers, whene ver 1030
the existence of such salts, isomers, and salts of isomers 1031
is possible: Lorcaserin; 1032
(5) Any material, compound, mixture or preparation 1033
containing any quantity of the following substances having a 1034
stimulant effect on the central nervous syste m, including 1035
their salts, isomers and salts of isomers: 1036
(a) Cathine ((+)-norpseudoephedrine); 1037
(b) Diethylpropion; 1038
(c) Fencamfamin; 1039
(d) Fenproporex; 1040
(e) Mazindol; 1041
(f) Mefenorex; 1042
(g) Modafinil; 1043
(h) Pemoline, including organometallic complexes and 1044
chelates thereof; 1045
(i) Phentermine; 1046
(j) Pipradrol; 1047
(k) Sibutramine; 1048
(l) SPA ((-)-1-dimethyamino-1,2-diphenylethane); 1049
(6) Any material, compound, mixture or preparation 1050
containing any quantity of the following substance, 1051
including its salts: 1052
(a) Butorphanol (including its optical isomers); 1053
(b) Eluxadoline (5-[[[(2S)-2-amino-3-[4-aminocarbonyl)- 1054
2,6-dimethylphenyl]-1-oxopropyl][(1S)-1-(4-phenyl-1 H- 1055
imidazol-2-yl)ethyl]amino]methyl]-2-methoxybenzoic acid) 1056
(including its optical isomers) and its salts, isomers, and 1057
salts of isomers; 1058
(c) Pentazocine; 1059 SB 763 35
(7) Ephedrine, its salts, optical isomers and salts of 1060
optical isomers, when the substance is the only active 1061
medicinal ingredient; 1062
(8) The department of health and senior services may 1063
except by rule any compound, mixture, or preparation 1064
containing any depressant substance listed in subdivision 1065
(1) of this subsection from the application of all or any 1066
part of sections 195.010 to 195.320 and sections 579.015 to 1067
579.086 if the compound, mixture, or preparation contains 1068
one or more active medicinal ingredients not having a 1069
depressant effect on the central nervous system, and if the 1070
admixtures are included there in in combinations, quantity, 1071
proportion, or concentration that vitiate the potential for 1072
abuse of the substances which have a depressant effect on 1073
the central nervous system. 1074
9. The department of health and senior services shall 1075
place a substance in Schedule V if it finds that: 1076
(1) The substance has low potential for abuse relative 1077
to the controlled substances listed in Schedule IV; 1078
(2) The substance has currently accepted medical use 1079
in treatment in the United States; and 1080
(3) The substance has limited physical dependence or 1081
psychological dependence liability relative to the 1082
controlled substances listed in Schedule IV. 1083
10. The controlled substances listed in this 1084
subsection are included in Schedule V: 1085
(1) Any compound, mixture or preparation containing 1086
any of the following narcotic drugs or their salts 1087
calculated as the free anhydrous base or alkaloid, in 1088
limited quantities as set forth below, which also contains 1089
one or more nonnarcotic active medicinal ingred ients in 1090
sufficient proportion to confer upon the compound, mixture 1091 SB 763 36
or preparation valuable medicinal qualities other than those 1092
possessed by the narcotic drug alone: 1093
(a) Not more than two and five -tenths milligrams of 1094
diphenoxylate and not less than twenty-five micrograms of 1095
atropine sulfate per dosage unit; 1096
(b) Not more than one hundred milligrams of opium per 1097
one hundred milliliters or per one hundred grams; 1098
(c) Not more than five-tenths milligram of difenoxin 1099
and not less than twenty-five micrograms of atropine sulfate 1100
per dosage unit; 1101
(2) Any material, compound, mixture or preparation 1102
which contains any quantity of the following substance 1103
having a stimulant effect on the central nervous system 1104
including its salts, isom ers and salts of isomers: 1105
pyrovalerone; 1106
(3) Any compound, mixture, or preparation containing 1107
any detectable quantity of pseudoephedrine or its salts or 1108
optical isomers, or salts of optical isomers or any 1109
compound, mixture, or preparation containi ng any detectable 1110
quantity of ephedrine or its salts or optical isomers, or 1111
salts of optical isomers; 1112
(4) Unless specifically exempted or excluded or unless 1113
listed in another schedule, any material, compound, mixture, 1114
or preparation which contain s any quantity of the following 1115
substances having a depressant effect on the central nervous 1116
system, including its salts: 1117
(a) Brivaracetam ((25)-2-[(4R)-2-oxo-4- 1118
propylpyrrolidin-1-yl]butanamide) (also referred to as BRV; 1119
UCB-34714; Briviact); 1120
(b) Ezogabine [N-[2-amino-4(4-fluorobenzylamino)- 1121
phenyl]-carbamic acid ethyl ester]; 1122 SB 763 37
(c) Lacosamide [(R)-2-acetoamido-N-benzyl-3-methoxy- 1123
propionamide]; 1124
(d) Pregabalin [(S)-3-(aminomethyl)-5-methylhexanoic 1125
acid]; 1126
(5) Any drug product in finished dosage formulation 1127
that has been approved by the U.S. Food and Drug 1128
Administration that contains cannabidiol (2 -[1R-3-methyl-6R- 1129
(1-methylethenyl)-2-cyclohexen-1-yl]-5-pentyl-1,3- 1130
benzenediol) derived from cannabis and no more than 0.1 1131
percent (w/w) residual tetrahydro cannabinols. 1132
11. If any compound, mixture, or preparation as 1133
specified in subdivision (3) of subsection 10 of this 1134
section is dispensed, sold, or distributed in a pharmacy 1135
without a prescription: 1136
(1) All packages of any compound, mixture, or 1137
preparation containing any detectable quantity of 1138
pseudoephedrine, its salts or optical isomers, or salts of 1139
optical isomers or ephedrine, its salts or optical isomers, 1140
or salts of optical isomers, shall be offered for sa le only 1141
from behind a pharmacy counter where the public is not 1142
permitted, and only by a registered pharmacist or registered 1143
pharmacy technician; and 1144
(2) Any person purchasing, receiving or otherwise 1145
acquiring any compound, mixture, or preparation containing 1146
any detectable quantity of pseudoephedrine, its salts or 1147
optical isomers, or salts of optical isomers or ephedrine, 1148
its salts or optical isomers, or salts of optical isomers 1149
shall be at least eighteen years of age; and 1150
(3) The pharmacist, intern pharmacist, or registered 1151
pharmacy technician shall require any person, prior to such 1152
person's purchasing, receiving or otherwise acquiring such 1153
compound, mixture, or preparation to furnish suitable photo 1154 SB 763 38
identification that is issued by a state or the federal 1155
government or a document that, with respect to 1156
identification, is considered acceptable and showing the 1157
date of birth of the person; 1158
(4) The seller shall deliver the product directly into 1159
the custody of the purchaser. 1160
12. Pharmacists, intern pharmacists, and registered 1161
pharmacy technicians shall implement and maintain an 1162
electronic log of each transaction. Such log shall include 1163
the following information: 1164
(1) The name, address, and signature of the purchaser; 1165
(2) The amount of the compound, mixture, or 1166
preparation purchased; 1167
(3) The date and time of each purchase; and 1168
(4) The name or initials of the pharmacist, intern 1169
pharmacist, or registered pharmacy technician who dispensed 1170
the compound, mixture, or preparation to the purchaser. 1171
13. Each pharmacy shall submit information regarding 1172
sales of any compound, mixture, or preparation as specified 1173
in subdivision (3) of subsection 10 of this section in 1174
accordance with transmission methods and frequency 1175
established by the department by regulation; 1176
14. No person shall dispense, sell, purchase, receive, 1177
or otherwise acquire quantities greater than those specified 1178
in this chapter. 1179
15. All persons who dispense or offer for sale 1180
pseudoephedrine and ephedrine products in a pharmacy shall 1181
ensure that all such products are located only behind a 1182
pharmacy counter where the public is not permitted. 1183
16. The penalties for a knowing or reckless violation 1184
of the provisions of subsec tions 11 to 15 of this section 1185
are found in section 579.060. 1186 SB 763 39
17. The scheduling of substances specified in 1187
subdivision (3) of subsection 10 of this section and 1188
subsections 11, 12, 14, and 15 of this section shall not 1189
apply to any compounds, mixtu res, or preparations that are 1190
in liquid or liquid-filled gel capsule form or to any 1191
compound, mixture, or preparation specified in subdivision 1192
(3) of subsection 10 of this section which must be 1193
dispensed, sold, or distributed in a pharmacy pursuant to a 1194
prescription. 1195
18. The manufacturer of a drug product or another 1196
interested party may apply with the department of health and 1197
senior services for an exemption from this section. The 1198
department of health and senior services may grant an 1199
exemption by rule from this section if the department finds 1200
the drug product is not used in the illegal manufacture of 1201
methamphetamine or other controlled or dangerous 1202
substances. The department of health and senior services 1203
shall rely on reports from law en forcement and law 1204
enforcement evidentiary laboratories in determining if the 1205
proposed product can be used to manufacture illicit 1206
controlled substances. 1207
19. The department of health and senior services shall 1208
revise and republish the schedules annu ally. 1209
20. The department of health and senior services shall 1210
promulgate rules under chapter 536 regarding the security 1211
and storage of Schedule V controlled substances, as 1212
described in subdivision (3) of subsection 10 of this 1213
section, for distribu tors as registered by the department of 1214
health and senior services. 1215
21. Logs of transactions required to be kept and 1216
maintained by this section and section 195.417 shall create 1217
a rebuttable presumption that the person whose name appears 1218 SB 763 40
in the logs is the person whose transactions are recorded in 1219
the logs. 1220
579.018. 1. A person commits the offense of coerced 1
criminal abortion by means of fraud if the person knowingly 2
and intentionally engages in the use of an abortion -inducing 3
drug on a pregnant woman without her knowledge or consent 4
with the intent to cause an abortion. 5
2. The offense of coerced criminal abortion by means 6
of fraud is a class B felony. 7
3. A prosecution of a person under this section shall 8
not be a defense against a prosecution under any other 9
provision of law, including murder, if the person commits 10
the offense of coerced criminal abortion by means of fraud 11
and the use of an abortion -inducing drug results in the 12
death or serious bodily inju ry of the pregnant woman. 13